Axogen Inc Overview
Industry: Medical Devices
Sector: Healthcare
AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida. AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves withou Read MoreAxogen Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Axogen Inc
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $48.6M (reported). Net loss was -$19.6M. Net income was $4.1M.
What changed
- Revenue reported to $48.6M.
Guidance / outlook
We expect 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Recent News
Earnings Per Share
Return on Equity
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
ROE
Company 0%
Sector Median 0%
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Net Margin
Company 0%
Sector Median 0%
Metric chart temporarily unavailable.
Leverage
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Leverage
Company 0
Sector Median 0
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.